Neuland Laboratories share news and announcements
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Last close ₹18,865.00down ₹70.00 (0.37%)BSE ₹18,924.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹18,935.00.
52-week range of traded prices to 23 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹24,204 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 48.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 12.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 May 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 53,34748.3% delivered
Neuland Laboratories share news and announcements
836 announcements, routine notices left out, newest first. Page 16 of 17.
Sep 2012
Aug 2012
1 Aug · Board meeting
Inter alia consider the unaudited financial results of the Company for the first quarter ended June 30, 2012.
Jul 2012
23 Jul · Address Change
Registered office of the company has been shifted to Sanali Info park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills, Hyderabad- 500034 from 204, Meridian plaza 6-3-953/1, Ameerpet, Hyderabad- 500016.6 Jul · Meeting
Annual General Meeting of the Company will be held on August 10, 2012.
Jun 2012
14 Jun · Updates
Board of Directors of the Company have vide a Resolution passed by Circulation dated May 30, 2012, approved transfer by way of Sale or long term lease or license of all or part of the Contract Research Services Business and Peptides Research Business of the Company, subject to the approval of members, through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 read with the Companies (passing of the resolution by postal ballot) Rules, 2011 and other relevant approvals.
May 2012
7 May · Corporate action
Board of Directors in its meeting held on May 03, 2012, have fixed the book closure from August 07, 2012 to August 10, 2012 (both days inclusive) for the purpose of ensuing Annual General Meeting.3 May · Management
Board of Directors of the Company at its meeting held on May 03, 2012 have approved reappointment of Mr. D. Saharsh Rao, as the Whole Time Director and President - Contract Research of the Company for a period of (3) three years with effect from June 01, 2012, subject to the approval of shareholders in ensuing Annual General Meeting.
Apr 2012
23 Apr · Board meeting
Inter-alia to consider the audited financial results of the Company for the year ended March 31, 2012.
Mar 2012
Feb 2012
17 Feb · Board Meeting Postponed
Neuland Laboratories Limited had informed the Exchange regarding a Board meeting to be held on February 19, 2012 inter alia, (1) To approve the Record Date for the purpose of deciding the shareholders who are eligible to apply for Equity Shares on rights basis in the proposed Issue, (2) To approve the size of the Issue, Issue price, ratio of Rights Entitlement, and other matters pertaining to the issue; (3) To approve the restated financial statement of the Company; (4) To ratify the appointment of bankers to the Issue; (5) To approve the Letter of Offer. The Company has now informed the Exchange that the meeting of the Board of Directors of the Company scheduled on February 19, 2012, is being postponed, till further notice, due to unexpected changes in travel schedule of some of the directors and consequent non-availability of quorum.16 Feb · Board meeting
Inter alia, (1) To approve the Record Date for the purpose of deciding the shareholders who are eligible to apply for Equity Shares on rights basis in the proposed Issue, (2) To approve the size of the Issue, Issue price, ratio of Rights Entitlement, and other matters pertaining to the issue; (3) To approve the restated financial statement of the Company; (4) To ratify the appointment of bankers to the Issue; (5) To approve the Letter of Offer.
Jan 2012
30 Jan · Board meeting
To inter-alia consider the Unaudited Financial Results of the Company for the quarter ended December 31, 2011.6 Jan · Management
Ms.Sarada Bhamidipati has been appointed as Company Secretary and Compliance Officer of the company w.e.f. January 03, 2012.
Dec 2011
Nov 2011
Oct 2011
18 Oct · Board meeting
To inter-alia consider the unaudited financial results of the company for the quarter ended September 30, 2011.14 Oct · Change in Registrar & Share Transfer Agent
Company has appointed M/s Karvy Computershare Private Limited as its RTA for handling all matters relating to the shares of the Company (both physical as well as demat mode) w.e.f. October 13, 2011 in place of M/s. Sathguru Management Consultants Private Limited. The details of the new RTA is as follows : Address : Karvy Computershare Pvt. Ltd., Plot No. 17 to 24, Vithal Rao Nagar, Madhapur, Hyderabad - 500081.
Aug 2011
8 Aug · Meeting
Shareholders at the Annual General Meeting of the Company held on August 05, 2011 have approved the following business : (1) Appointed Mr. Will Mitchell, as Director retiring by rotation; (2) Appointed Mr. S.B. Budhiraja, as Director retiring by rotation; (3) Appointed M/s. K S Aiyar & Co. as Auditors for the year ending March 31, 2012; (4) Approved Dr. Christopher M. Cimarusti to hold an office or place of profit for a period of 5 years; (5) Payment of commission to Non Executive Directors for a period of 5 years commencing April 01, 2011 @ 1% of the net profit of the Company.
Jul 2011
20 Jul · Board meeting
To inter alia consider the unaudited financial results of the Company for the quarter ended June 30, 2011.7 Jul · Corporate action
Board of Directors of the Company at its meeting held on July 07, 2011, inter alia, has accorded consent to a Rights Issue of Equity Shares not exceeding Rs. 12 crores. Further the Board at this meeting also constituted a Board Committee called the Rights Issue Committee to finalise the Rights ratio, issue price, record date and all other procedural modalities relating to the proposed Rights Issue.